Citigroup’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-197,565
| Closed | -$2.21M | – | 7787 |
|
|
2017
Q3 | $2.21M | Buy |
197,565
+89,216
| +82% | +$984K | ﹤0.01% | 2559 |
|
|
2017
Q2 | $1.19M | Buy |
108,349
+38,727
| +56% | +$387K | ﹤0.01% | 3128 |
|
|
2017
Q1 | $682K | Sell |
69,622
-45,455
| -39% | -$454K | ﹤0.01% | 3601 |
|
|
2016
Q4 | $1.24M | Buy |
115,077
+65,701
| +133% | +$657K | ﹤0.01% | 3462 |
|
|
2016
Q3 | $506K | Buy |
49,376
+21,549
| +77% | +$235K | ﹤0.01% | 3886 |
|
|
2016
Q2 | $363K | Sell |
27,827
-22,464
| -45% | -$294K | ﹤0.01% | 3967 |
|
|
2016
Q1 | $553K | Buy |
50,291
+23,475
| +88% | +$209K | ﹤0.01% | 4018 |
|
|
2015
Q4 | $247K | Buy |
26,816
+22,070
| +465% | +$185K | ﹤0.01% | 4546 |
|
|
2015
Q3 | $33K | Sell |
4,746
-10,744
| -69% | -$92K | ﹤0.01% | 5706 |
|
|
2015
Q2 | $152K | Buy |
15,490
+4,189
| +37% | +$38.2K | ﹤0.01% | 4671 |
|
|
2015
Q1 | $100K | Sell |
11,301
-10,591
| -48% | -$84.4K | ﹤0.01% | 5030 |
|
|
2014
Q4 | $191K | Buy |
21,892
+17,671
| +419% | +$143K | ﹤0.01% | 4735 |
|
|
2014
Q3 | $29K | Sell |
4,221
-189
| -4% | -$1.13K | ﹤0.01% | 5674 |
|
|
2014
Q2 | $23K | Sell |
4,410
-12,010
| -73% | -$58.4K | ﹤0.01% | 5745 |
|
|
2014
Q1 | $75K | Sell |
16,420
-6,875
| -30% | -$33.2K | ﹤0.01% | 5222 |
|
|
2013
Q4 | $118K | Buy |
23,295
+8,716
| +60% | +$41.9K | ﹤0.01% | 5124 |
|
|
2013
Q3 | $73K | Sell |
14,579
-6,088
| -29% | -$33.9K | ﹤0.01% | 4979 |
|
|
2013
Q2 | $102K | Buy |
+20,667
| New | +$98.3K | ﹤0.01% | 4847 |
|
Citigroup's SCLN Position: Q4 2017 in Review
Citigroup sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 197,565 shares — an estimated $2.21M sold.
Citigroup first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $2.21M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Citigroup reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Citigroup sold 197,565 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $2.21M.
- Citigroup first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Citigroup's Sciclone Pharmaceuticals Inc position peaked at $2.21M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Citigroup's 13F filing for Q4 2017, filed 12 Feb 2018.